Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

Weaker effect of HIV-1 on mortality in children <5 y in areas of high malaria transmission specifically, analogous to the comparatively weak effect of HIV-1 on incidence in this group: RR = 1.5 at CD4 >500/μL, RR = 2.0 at CD4 200–499/μL, and RR = 5.0 at CD4 <200/μL.

Stronger decrease with age in malaria incidence: RRs compared to <5 y of 0.30 for 5–14y and 0.05 for >15 y in high malaria transmission areas, and 0.60 for 5–14 y and 0.10 for >15 y for areas of low and unstable malaria transmission including southern African countries.

1.0 (0.13–15)

4.0 (0.45– 59)

No decrease with age in malaria incidence at any malaria transmission intensity.

4.4 (0.54–37)

12.5 (1.5–153)

Stronger decrease with age in malaria CFR: 1.2% in <5 y at all malaria transmission intensities, 0.8% in >5 y at low and unstable transmission, 0.15% in >5 y at high transmission.

n.a.

4.0 (0.53–107)

No decrease with age in malaria CFR at any transmission intensity.

n.a.

5.7 (0.77–114)

HIV-1 increases malaria incidence also in children <5 y in areas of high malaria transmission.

Lower HIV prevalence in children <14 y: lower bound country estimates by UNAIDS/WHO††

1.3 (0.20–27)

3.9 (0.47–111)

Higher HIV prevalence in children <14 y: upper bound country estimates by UNAIDS/WHO††

1.5 (0.23–29)

6.8 (1.08–119)

*N.A., not applicable; CFR, malaria case-fatality rate; RR, relative risk; UNAIDS, Joint United Nations Programme on HIV/AIDS/WHO.†Continental total. In none of the scenarios did the ranking of countries in magnitude of HIV impact change appreciably. Across all scenarios, the minimum and maximum increases (in brackets) were always in Senegal or Mauritania, and in Botswana, respectively. An exception was the scenarios of lower HIV prevalence in adults, for which the lowest malaria impacts would be in Sierra Leone and Somalia.‡The overall relative risk for malaria mortality due to HIV-1 in stable HIV-1 epidemics is now 2.1, i.e., does no longer fit the observed value of ≈4 (see Methods, Malaria mortality and Effect of HIV).§The overall relative risk for malaria mortality due to HIV-1 in stable HIV-1 epidemics is now 5.7, i.e., does no longer fit the observed value of ≈4 (see Methods, Malaria death and effect of HIV).¶As in Western populations (25).#To allow for a possible initial drop in CD4 immediately upon infection, i.e., still before seroconversion.**Cross-country median lowerbound estimate of HIV prevalence in adults 2.7%; cross-country median upperbound HIV prevalence estimate 8.8% (compared to default point estimate of 4.8%).††Cross-country median lowerbound estimate of HIV prevalence in children <14 years of 0.2%; cross-country median upperbound HIV prevalence estimate 1.1% (compared to default point estimate of 0.5%).

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.